Best Practice and Physician-Driven Networks
Executive Summary
Lower prices often didn't result in increased market share. As a result, in the early 1990s we saw a kind of backlash against the bigger-is-better mentality, as suppliers regarded skeptically any group that had a membership too large to effectively manage, while rewarding (with better prices) those groups, particularly investor-owned hospital systems, that could mandate compliance.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.